Scopus Biopharma

Scopus Biopharma FCF per Share

The Free Cash Flow per Share of Scopus Biopharma (SCPS) as of Nov 19, 2026 is -0.39 USD. In the previous year, Free Cash Flow per Share was -0.54 USD — a change of -28.87% (higher).

FCF per Share

-0.39USD

YoY

-28.87%

Last updated:

Free Cash Flow per Share of Scopus Biopharma is 2022 -0.39 USD. Free Cash Flow per Share of Scopus Biopharma was 2021 -0.54 USD. It decreases by -28.87% higher compared to the previous year.

The Scopus Biopharma FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2017
-0.01 USD
Jan 1, 2018
-0.05 USD
Jan 1, 2019
-0.14 USD
Jan 1, 2020
-0.17 USD
Jan 1, 2021
-0.54 USD
Jan 1, 2022
-0.39 USD
The Scopus Biopharma FCF per Share history
YEARFCF per ShareYoY
-0.39USD-28.87%
-0.54USD+220.99%
-0.17USD+18.95%
-0.14USD+182.70%
-0.05USD+355.07%
-0.01USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

Free Cash Flow per Share of Scopus Biopharma is -0.39 USD in 2022.

Free Cash Flow per Share of Scopus Biopharma changed from -0.54 USD to -0.39 USD, representing a -28.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Scopus Biopharma

All Key Metrics — Scopus Biopharma